SCHEMBL1301270

SCHEMBL1301270

COc1nc2c(cc1NCc1ccccc1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.47
▸ KMT2A Q03164 2/20 0.37
▸ GSK3B P49841 2/20 0.36
▸ PDE10A Q9Y233 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ ASPH Q12797 1/20 0.35
▸ KDM8 Q8N371 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ TP53 P04637 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ YWHAH Q04917 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ DPP4 P27487 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301276 1.00 METTL3 (0.47) METTL3KMT2AGSK3BPDE10AGAA
SCHEMBL1301713 0.94 METTL3 (0.49) METTL3KMT2AGSK3BPDE10AKDM4E
SCHEMBL1301707 0.94 METTL3 (0.49) METTL3KMT2AGSK3BPDE10AKDM4E
SCHEMBL1302316 0.92 METTL3 (0.46) METTL3KMT2AGSK3BKDM4ESMN1; SMN2
SCHEMBL1302306 0.92 METTL3 (0.46) METTL3KMT2AGSK3BKDM4ESMN1; SMN2
SCHEMBL1300638 0.91 METTL3 (0.43) METTL3GSK3BPDE10AKDM4EALDH1A1
SCHEMBL1301560 0.91 METTL3 (0.45) METTL3GSK3BPDE10AKDM4EASPH
SCHEMBL1300644 0.91 METTL3 (0.43) METTL3GSK3BPDE10AKDM4EALDH1A1
SCHEMBL1301563 0.91 METTL3 (0.45) METTL3GSK3BPDE10AKDM4EASPH
SCHEMBL1300920 0.91 METTL3 (0.46) METTL3KMT2AGSK3BPDE10AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885KMT2A 1154/4885GSK3B 524/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885KMT2A 1154/4885GSK3B 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback